Company: Sun Pharmaceuticals Industries Ltd
Pros:
The company has shown consistent growth over years.
The financial numbers looks good.
Risks:
The stock has corrected upto 33% due to Ranbaxy merger issues.
The company also informed that sales/profit will remain flat for this year due to
one time payments related to Ranbaxy merger. From what I understand,
these are one time issues and the growth might be muted for the next two quarters.
The company should be back in track from next financial year.
Decision: Planning to increase allocation.
Views are most welcome.
| Subscribe To Our Free Newsletter |
